Trial Profile
Change from Vitamin K Antagonist to Factor Xa inhibitor Improves Pulse Wave Velocity
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 13 Aug 2019
Price :
$35
*
At a glance
- Drugs Rivaroxaban (Primary) ; Warfarin
- Indications Atherosclerosis
- Focus Therapeutic Use
- Acronyms K2-SUMMIT 3
- 11 Aug 2019 Status changed from recruiting to completed.
- 12 Feb 2015 New trial record